916764-93-7

Usage

Molecular Structure

The compound has a complex structure that includes a pyrazolo-pyrimidine ring and a biphenyl group.

Heterocyclic Compound

The pyrazolo-pyrimidine ring is a heterocyclic compound, which means it contains atoms of different elements in its ring structure.

Medicinal Chemistry

The pyrazolo-pyrimidine ring is commonly used in medicinal chemistry due to its potential biological activities.

Biological Activity

The compound's specific structural and functional properties make it potentially useful in pharmaceutical research and drug design efforts.

Biphenyl Group

The presence of the biphenyl group suggests the compound may have specific binding and activity, particularly within biological systems.

Upstream product

• 2567-29-5 p-phenylbenzyl bromide 
• 1351961-59-5 7-(4-methoxybenzyl)-5-methyl-1,7-dihydro-4H-pyrazolo[3,4-d]pyrimidine-4,6(5H)-dione 
• 916764-92-6 2-(biphenyl-4-ylmethyl)-7-(4-methoxybenzyl)-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 

Downstream Products

• 916764-94-8 2-(biphenyl-4-ylmethyl)-6-chloro-5-methyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 
• 1160490-73-2 2-(biphenyl-4-ylmethyl)-7-isobutyl-5-methyl-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione 
• 916764-95-9 2-(biphenyl-4-ylmethyl)-6-(1-hydroxy-2-methylpropan-2ylamino)-5-methyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 

Relevant academic research and scientific papers

ORGANIC COMPOUNDS

1- or 2- or 7-(substituted)-3-(optionally hetero)arylamino-[lH, 2H]-pyrazolo[3,4-d] pyrimidine-4,6(5H, 7H)-dione derivatives, in free, salt or prodrug form, are useful as pharmaceuticals, particularly as phosphodiesterase 1 inhibitors, useful for the treatment of diseases involving disorders of the dopamine Dl receptor intracellular pathway, such as Parkinson's disease, depression, narcolepsy and damage to cognitive function, e.g., in schizophrenia or disorders that may be ameliorated through enhanced progesterone - signaling pathway, e.g., female sexual dysfunction.

ORGANIC COMPOUNDS

The invention provides novel 7,8-dihydro-imidazo[l,2-α]pyrazolo[4,3-e]pyrimidin-4- one compounds and 7,8,9-trihydro-[lHor 2/f]-pyrimido [l,2-a]pyrazolo[4,3- e]pyrimidin-4(5H)-one compounds, substituted at the 1 or 2 position with C2-g allcyl, C3-9 cycloalkyl, heteroarylalkyl, or substituted arylalkyl, in free, salt or prodrug form, processes for their production, their use as pharmaceuticals, particularly as PDEl inhibitors, and pharmaceutical compositions comprising them.